Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD

Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD

Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD

Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD

Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD

Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD

Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD

Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD

Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD

Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD

Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD

Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD

Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD

Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD

How Doctors Spot Hidden Myeloma Risks Early | Bruno Paiva, PhD

How Doctors Spot Hidden Myeloma Risks Early | Bruno Paiva, PhD

MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD

MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD

Reduced Cardiac Risk Factors in AL Amyloidosis with D-VCd | Vaishali Sanchorawala, MD

Reduced Cardiac Risk Factors in AL Amyloidosis with D-VCd | Vaishali Sanchorawala, MD

Myeloma Bispecific Antibodies in the Real World: Practical Insights | Sikander Ailawadhi, MD

Myeloma Bispecific Antibodies in the Real World: Practical Insights | Sikander Ailawadhi, MD

CAR-T Dosing Matters: Real-World Data on Effectiveness and Outcomes | Ran Reshef, MD

CAR-T Dosing Matters: Real-World Data on Effectiveness and Outcomes | Ran Reshef, MD